cis-4-Hydroxy-L-proline

cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension^{[1][2][3][4][5][6][7][8][9][10]}. In Vitro:cis-4-Hydroxy-L-proline (100-200 μg/mL; 1 week) inhibits the accumulation of collagenous and noncollagenous proteins in the culture medium in the in vitro co-culture experiment of rat Schwann cells (SC) and dorsal root ganglion neurons^[1].
cis-4-Hydroxy-L-proline (200 μg/mL; 6 h) reduces the proportion of collagen synthesis in total protein synthesis and increases the degradation proportion of newly synthesized collagen in freshly isolated chick tendon fibroblasts^[2].
cis-4-Hydroxy-L-proline (3200-32000 μg/mL; 24 h) significantly reduces the production of albumin and urea by hepatocytes^[3].
In Vivo:cis-4-Hydroxy-L-proline (285-903 mg/kg; p.o.; 28 days) causes signs of liver damage in rats, showing elevated alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT)^[3].
cis-4-Hydroxy-L-proline (200 mg/kg; s.c.; twice daily; 30 days) partially prevents the accumulation of collagen in the lungs and partially improves the decrease in lung compliance in the Bleomycin (HY-108345)-induced pulmonary fibrosis model experiment of hamsters^[4].
cis-4-Hydroxy-L-proline (200 mg/kg; s.c.; injected alone for 3 days first and then co-injected with dihydrotestosterone for 10 days) significantly reduces the wet weight of the prostate, inhibits the proliferation and differentiation of prostatic glandular cells in response to androgen stimulation in Androgen-induced prostate growth model in prepubertal castrated guinea pigs^[5].
CHOP-PEG (polymeric prodrug of cis-4-Hydroxy-L-proline, 0.8 mg by continuous s.c.; 10 mg by single s.c.; 40 mg by single i.v.; 90 mg by single intratracheal injection; 7 days) can prevent and reverse chronic hypoxic pulmonary hypertension in the rat hypoxic pulmonary hypertension model^[6].